WSJ: Moderna's Cancer Vaccine Passes First Test, But Stock Priced for 'Wild Successes,' Reinforcing DeepValue WAIT Stance

What happened

Moderna's Phase 3 melanoma data for V940/intismeran reportedly passed its first major test, triggering a 177% stock surge in August, but the stock has since retraced roughly 25% to around $140. The WSJ argues that even after the pullback, the share price assumes 'wild successes,' implying that the market is pricing in near-certain regulatory approval and commercial success across oncology and respiratory programs. DeepValue's latest report concurs, rating MRNA a WAIT with conviction 3.5 and a base-case intrinsic value of $135, noting that current financials don't support the valuation. Q2 2026 revenue was only $145 million, H1 net loss was $2.1 billion, and cash is guided to $4.7-5.2 billion by year-end after a $950 million settlement, leaving little room for execution missteps. Key near-term catalysts that could justify or deflate the valuation include melanoma regulatory filing, 2027 flu launch preparations, and evidence that EU RSV orders convert to actual revenue.

Implication

DeepValue's analysis suggests an attractive entry around $115 and a trim above $170, with a re-assessment window of 3-6 months. The stock is highly sensitive to near-term catalysts: without a melanoma filing, clear flu contracting, or RSV order conversion, the current price embeds excessive optimism. Sentiment is crowded and fragile, as shown by the 25% one-day reversal after the initial surge, so risk-reward is poor for new buyers at current levels. Existing holders should consider trimming into strength above $170 or if catalysts fail to materialize by early 2027. Conversely, a pullback toward $115 or successful execution on the catalyst checklist would improve the risk-reward and support adding.

Thesis delta

The WSJ article aligns with DeepValue's existing WAIT rating, reinforcing the view that the stock is priced for success that has not yet been secured. No change to the base-case valuation or catalyst checklist, but the external skepticism lowers the odds of near-term multiple expansion. We maintain WAIT and would only increase conviction if the stock approaches $115 or if melanoma filing and flu contracting are disclosed.